RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

Drug Monitoring/Screening

A 5-year analyses from Millennium Health showed that patients undergoing drug monitoring, or UDT, as part of chronic opioid therapy, among other reasons, tested positive for a broad range of other unexpected medications. Plus, a look at buprenorphine and gabapentinoid abuse and drug-detection trends.
Basic principles in urine drug monitoring (UDM) are reviewed and applied to a patient testing positive for oxycodone and amphetamine.
Strategies for ordering, understanding, and communicating opioid therapy screening results.
FDA makes a motion to increase medication-assisted treatment for opioid addiction.
Gaining clearance from the Food and Drug Administration (FDA), 2 new drug screening tests offer practitioner immediate, in-office results for the 5 most commonly abused opioid-derived drugs and for fentanyl.
When a clinician orders urine drug testing for a patient prescribed chronic opioid therapy (COT), it is essential that the results are interpreted correctly because they often have significant clinical implications. A positive test result showing drugs and/or metabolites found in urine is easily understood.
Benzodiazepines, which first entered the US pharmaceutical market in the early 1960s, fall under the class of drugs referred to as sedative-hypnotics.1 Benzodiazepines possess anxiolytic, anticonvulsant, hypnotic, sedative, muscle relaxant, and amnesic effects.2 They are generally well-tolerated, safe, and effective for short-term use.
Interpreting urine drug tests in pain patients treated with oxycodone requires an understanding that oxymorphone, although considered a minor metabolite, can sometimes equal or exceed urine concentrations of oxycodone.
close X
SHOW MAIN MENU
SHOW SUB MENU